Skip to content

Emdogain and Straumann Bone Ceramic in Infrabony Defects

Randomised, Controlled, Clinical Study to Compare the Effect of a Combination of Enamel Matrix Proteins and Straumann Bone Ceramic With Autogenous Bone in Deep-wide Intrabony Defects

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00906776
Enrollment
19
Registered
2009-05-21
Start date
2007-04-30
Completion date
2012-07-31
Last updated
2016-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

Randomised, controlled, clinical study to compare the effect of the combination of bone ceramic and enamel matrix proteins (test) versus autogenous bone graft alone (control) in the treatment of deep-wide intrabony defects

Detailed description

30 subjects (15 test and 15 control) diagnosed with moderate to severe periodontitis (Armitage, 1999) will be enrolled in the study and randomized to either the test or the control group. The surgical procedure shall be performed within 15 days from the baseline visit of the subjects and will be the same for both groups. In both groups, the flap is replaced subsequently. In total 5 visits per patient are scheduled in this study. The total study duration for each patient should be 12 +/- 2 weeks. The study devices Emdogain® and Straumann Bone Ceramic are CE-marked, and approved by the FDA. One center in France will participate.

Interventions

DEVICEEmdogain PLUS

Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery

Autogenous bone application during periodontal surgery

Sponsors

Institut Straumann AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Males and females must be at least 18 years and not more than 75 years of age * The patient will have to be able to understand and sign the informed consent prior to starting the study. * The patient also will have to have the ability and the willingness to comply with all study requirements. * The patients will be in good general health without any systemic diseases. * The teeth included in the study will be mandibular molars, maxillary and mandibular premolars, and canines. * The patients will have to have at least one defect with pocket depth ≥ 5 mm. * Intra-bony defects will have to have 1 or 2-wall morphology (at least 2/3 of the defect). * Depth of the intrabony component of at least 3 mm * The selected sites will have to have vertical intra-bony component ≥ 3 mm and an angle ≥ 30 degrees as assessed from standardized intra-oral radiographs. * Oral hygiene parameters: Plaque Index (PI) ≤ 20 % and bleeding on probing (BoP) ≤ 20%

Exclusion criteria

* Heavy smokers: more than 20 cigarettes per day * Mucosal diseases such as erosive lichen planus * History of local radiation therapy * Presence of oral lesions (such as ulceration, malignancy) * Teeth with untreated endodontic or cardiologic problems * Physical handicap that will interfere with patient's ability to exercise good oral hygiene on a regular basis. * Patients presenting antibiotic treatment within the 3 months preceding the surgical procedure. * Patients using anti-inflammatory drugs on a regular basis. * Intra-bony defects with a 3-wall morphology. * Intra-bony defects with furcation involvement. * Incisors and maxillary molars, will be excluded. * Alcoholism or chronically drug abuse causing systemic compromize * Medical conditions requiring prolonged use of steroids * Current pregnancy at the time of recruitment and/or breastfeeding women. * Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.

Design outcomes

Primary

MeasureTime frameDescription
Change in Clinical Attachment Level (CAL)Baseline and 12 monthsCAL is calculated as the sum of Probing Pocket Depth (PPD) and Recession (REC). PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket. REC is measured using a periodontal probe from the gingival margin to the cemento-enamel junction (CEJ).

Secondary

MeasureTime frameDescription
Change in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone DefectBaseline and 6 months
Change in Probing Pocket Depth (PPD)Baseline and 12 monthsPPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket.
Change in Clinical Attachment Level (CAL)Baseline and 6 monthsCAL is calculated as the sum of Probing Pocket Depth (PPD) and Recession (REC). PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket. REC is measured using a periodontal probe from the gingival margin to the cemento-enamel junction (CEJ).

Countries

France

Participant flow

Participants by arm

ArmCount
Emdogain PLUS
Straumann Emdogain in combination with Straumann BoneCeramic
11
Autogenous Bone
Autogenous bone from the patient
8
Total19

Baseline characteristics

CharacteristicEmdogain PLUSAutogenous BoneTotal
Age, Continuous36.9 years
STANDARD_DEVIATION 8.9
31.9 years
STANDARD_DEVIATION 8.6
34.8 years
STANDARD_DEVIATION 8.6
Sex: Female, Male
Female
7 Participants4 Participants11 Participants
Sex: Female, Male
Male
4 Participants4 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
1 / 110 / 8
serious
Total, serious adverse events
0 / 110 / 8

Outcome results

Primary

Change in Clinical Attachment Level (CAL)

CAL is calculated as the sum of Probing Pocket Depth (PPD) and Recession (REC). PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket. REC is measured using a periodontal probe from the gingival margin to the cemento-enamel junction (CEJ).

Time frame: Baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Clinical Attachment Level (CAL)-2.86 millimetersStandard Deviation 1.43
Autogenous BoneChange in Clinical Attachment Level (CAL)-2.44 millimetersStandard Deviation 1.08
Secondary

Change in Clinical Attachment Level (CAL)

CAL is calculated as the sum of Probing Pocket Depth (PPD) and Recession (REC). PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket. REC is measured using a periodontal probe from the gingival margin to the cemento-enamel junction (CEJ).

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Clinical Attachment Level (CAL)-2.44 mmStandard Deviation 0.95
Autogenous BoneChange in Clinical Attachment Level (CAL)-2.25 mmStandard Deviation 1.1
Secondary

Change in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect-2.02 mmStandard Deviation 1.8
Autogenous BoneChange in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect-2.13 mmStandard Deviation 1.47
Secondary

Change in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect

Time frame: Baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect-2.26 mmStandard Deviation 1.99
Autogenous BoneChange in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect-2.29 mmStandard Deviation 1.48
Secondary

Change in Probing Pocket Depth (PPD)

PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket.

Time frame: Baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Probing Pocket Depth (PPD)-3.36 millimetersStandard Deviation 1.42
Autogenous BoneChange in Probing Pocket Depth (PPD)-2.75 millimetersStandard Deviation 1.13
Secondary

Change in Probing Pocket Depth (PPD)

PPD is measured using a periodontal probe from the gingival margin to the bottom of the pocket.

Time frame: Baseline and 6 months

ArmMeasureValue (MEAN)Dispersion
Emdogain PLUSChange in Probing Pocket Depth (PPD)-2.78 mmStandard Deviation 1.18
Autogenous BoneChange in Probing Pocket Depth (PPD)-2.56 mmStandard Deviation 1.18

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026